Iris Acquisition CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Iris Acquisition Corp is asking stockholders to approve a business combination with Liminatus Pharma, involving a merger and stock issuance, at a special meeting on March 4, 2025.
Iris Acquisition Corp discloses a late notification regarding a loan provided to facilitate the acquisition of its sponsor's former managing member.
Iris Acquisition Corp is seeking stockholder approval to extend the deadline for completing a business combination to March 31, 2025, with a potential further three-month extension, and has scheduled a special meeting for December 20, 2024, to vote on the matter.
Iris Acquisition Corp is seeking stockholder approval to extend the deadline for completing a business combination to December 31, 2024, due to recent challenges with its proposed merger with Liminatus Pharma.
Iris Acquisition Corp. is asking its stockholders to approve a business combination with Liminatus Pharma, a clinical-stage biopharmaceutical company.